In this episode of Clinical Capital Conversations, Dr. Peter M. Kovacs speaks with Károly Szántó about venture studios, calculated risk, and what it really takes to turn promising innovation into execution.

We cover:

• How a non-linear career becomes a competitive advantage

• Why focus beats speed in early-stage venture building

• The difference between high risk and calculated risk

• What university spinouts are missing, and how to fix it through market partnership

• How ecosystems change through examples, not speeches

• What investors should do diligence to avoid science-driven capital burn

Subscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital. Investors, founders, and operators welcome.

Timecode:

00:00 Introduction and Guest Welcome

00:26 Karoly's Career Journey

01:16 Discovering Sales and Business Development

03:46 Embracing Entrepreneurship

07:55 Building Uni Prisma Venture Studio

08:49 Venture Capital Experience

13:57 Focus on Healthcare and Impact

18:09 Challenges and Future Vision

22:49 Conclusion and Final Thoughts

Subscribe to Clinical Capital Conversations for unfiltered discussions at the crossroads of science and capital. Investors, founders, and operators welcome.

Links:

Peter M. Kovacs LinkedIn: https://www.linkedin.com/in/petermkovacs/

Peter M. Kovacs Personal Website:https://www.petermkovacs.com/

PMK Group Website: https://www.pmk-group.com/

Guests:

Károly Szántó: https://www.linkedin.com/in/karolyszanto1/